SION

Sionna Therapeutics, Inc.
CAPPED RATING

Sionna Therapeutics, Inc. (SION) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B+
Factor Score 3.7 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
D-
Factor Score 1.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.5
EV / EBITDA 0.5
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -43.6%
Price Return 12M -90.9%
Catalyst Signal 0.00
Market Cap $150.6M
TTM Revenue N/A
Price / Sales N/A
ROE -39.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B+ (3.7) C- (2.0) C- (2.0) D- (1.0) C+ (2.6) C (2.3)
2026-11-07 B+ (3.8) C- (2.0) C- (2.0) D (1.4) F (0.0) D+ (1.8)
2026-10-31 B+ (3.7) C- (1.9) C- (2.0) F (0.3) F (0.0) D+ (1.6)
2026-10-24 B+ (3.7) C- (1.9) C- (2.0) F (0.3) F (0.0) D+ (1.6)
2026-10-17 B+ (3.7) C- (1.9) C- (2.0) F (0.4) F (0.0) D+ (1.6)
Page 1 of 4